S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
NASDAQ:KRBP

Kiromic BioPharma (KRBP) Stock Price, News & Analysis

$2.77
-0.30 (-9.77%)
(As of 03/27/2024 ET)
Today's Range
$2.77
$3.09
50-Day Range
$1.25
$3.46
52-Week Range
$0.16
$8.97
Volume
1,537 shs
Average Volume
4,841 shs
Market Capitalization
$3.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
KRBP stock logo

About Kiromic BioPharma Stock (NASDAQ:KRBP)

Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company develops ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

KRBP Stock Price History

KRBP Stock News Headlines

Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Kiromic BioPharma Announces Uplisting to OTCQB Market
Kiromic BioPharma Inc Ordinary Shares
Staidson Beijing Biopharma (300204)
KRBP - Kiromic BioPharma, Inc.
Kiromic BioPharma Announces Reverse Stock Split
See More Headlines
Receive KRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiromic BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/18/2024
Today
3/28/2024
Next Earnings (Estimated)
4/15/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:KRBP
Fax
N/A
Employees
31
Year Founded
N/A

Profitability

Net Income
$-20,950,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($7.25) per share

Miscellaneous

Free Float
1,246,000
Market Cap
$3.57 million
Optionable
Not Optionable
Beta
1.99
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Pietro Bersani CPA (Age 56)
    J.D., CEO & Director
    Comp: $546.76k
  • Dr. Scott Dahlbeck M.D. (Age 62)
    Pharm.D., PharmD, Chief of Staff
    Comp: $385.36k
  • Mr. Brian Hungerford (Age 49)
    CFO & Principal Accounting Officer
  • Dr. Leonardo Mirandola Ph.D. (Age 43)
    Chief Scientific Officer & Interim COO

KRBP Stock Analysis - Frequently Asked Questions

How have KRBP shares performed in 2024?

Kiromic BioPharma's stock was trading at $0.87 at the beginning of the year. Since then, KRBP shares have increased by 218.4% and is now trading at $2.77.
View the best growth stocks for 2024 here
.

When is Kiromic BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 15th 2024.
View our KRBP earnings forecast
.

How were Kiromic BioPharma's earnings last quarter?

Kiromic BioPharma, Inc. (NASDAQ:KRBP) issued its quarterly earnings results on Monday, March, 18th. The company reported ($4.16) EPS for the quarter.

When did Kiromic BioPharma's stock split?

Kiromic BioPharma shares reverse split on the morning of Monday, March 13th 2023. The 1-30 reverse split was announced on Monday, March 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did Kiromic BioPharma IPO?

Kiromic BioPharma (KRBP) raised $16 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 1,200,000 shares at a price of $12.00-$14.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO and Paulson Investment Company was co-manager.

How do I buy shares of Kiromic BioPharma?

Shares of KRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KRBP) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners